Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis
A live, multi-source view of Madrigal Pharmaceuticals, Inc. (MDGL): real-time price, technical indicators, Wall Street analyst consensus, recent news sentiment and social buzz — aggregated into one place so you can size up the stock at a glance.
About Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Sector: Healthcare · Industry: Biotechnology · United States · 915 employees · madrigalpharma.com
Key statistics · as of 2026-09-05
As of 2026-09-05, Madrigal Pharmaceuticals, Inc. (MDGL) had a market capitalization of $12.50B (forward 56.2) and a beta of -0.99; the shares traded in a 52-week range of $393.61 – $615.00 (19.6% over the year).
- Market cap
- $12.50B
- Enterprise value
- $12.01B
- Forward P/E
- 56.2
- Price / book
- 23.86
- EPS (trailing)
- $-14.00
- EPS (forward)
- $9.63
- Payout ratio
- 0.0%
- 52-week range
- $393.61 – $615.00
- 52-week change
- 19.6%
- Beta
- -0.99
- Average volume
- 352,424
- Shares outstanding
- 23.1M
- Short % of float
- 10.30%
- Profit margin
- -25.3%
Fundamental figures are recorded once every few days, dated above; they are not live and can differ from the interactive tiles.
Last universe scan · 2026-09-10
In RapidTradeView’s 2026-09-10 scan of the US universe, Madrigal Pharmaceuticals, Inc. (MDGL) last closed at $546.66 (the last completed close before that scan).
Technicals at the scan: RSI 57 (neutral territory), price +3.1% versus its 20-day average, 20-day versus 50-day average spread -0.0%, MACD histogram 1.57.
Sentiment inputs: StockTwits 100% bullish; analyst consensus score 78/100.
Next scheduled company event: in 55 days from the scan date.
Scan values are recorded once per trading day and are not live quotes; the interactive tiles above update in real time.
Smart Money · last 90 days
Members of Congress disclosed 0 buys and 0 sells of MDGL; corporate insiders filed 0 buys and 11 sells (2 distinct filers, latest disclosure 2026-08-20). Filings arrive days to weeks after the trade and are not a live signal. Most active filers: William John Sibold (0B/10S), Shannon T. Kelley (0B/1S). Who is trading what
RapidTradeView pick record
MDGL has been a daily pick 1 time; 1 of 1 graded picks beat SPY over the following five trading days. Most recent: 2026-08-24, rank #2, +5.01% versus SPY (beat). Full scoreboard
What this page covers
RapidTradeView pulls Madrigal Pharmaceuticals, Inc. (MDGL) data from multiple independent sources and combines it into a single dashboard. Below the summary you’ll find live, interactive tiles for each of the following:
- Price & chart — real-time quote with pre/post-market moves and a line or candlestick chart.
- Technical indicators — RSI, MACD, moving averages, Bollinger Bands, volume and support/resistance, distilled into one overall signal.
- Analyst consensus — the buy/hold/sell breakdown and price targets published by Wall Street analysts.
- News sentiment — recent headlines, each scored for tone so the prevailing narrative is obvious.
- Earnings — current EPS, year-over-year change and the next scheduled earnings date.
- Social buzz — Reddit mention volume and StockTwits sentiment for the retail-trader angle.
How to read the signals
No single indicator tells the whole story. A bullish technical reading paired with a cautious analyst consensus, or strong social buzz against weak earnings, is exactly the kind of tension this view is built to surface. RapidTradeView’s signals are generated by deterministic, statistical models — they describe what the data is doing, they are not personalised recommendations to buy or sell MDGL.
Disclaimer: RapidTradeView is an educational sentiment-aggregation tool, not a licensed financial adviser, broker, or dealer. Nothing here is financial, investment, tax, or legal advice. Markets are risky and you can lose money. Always do your own research and consult a qualified professional before making any investment decision.